📋 Tender Overview
The First In-Class Non-Opioid Drug For Treating Moderate, Severe, And Persistent Pain With No Addiction Nor Tolerance
Breakthrough In Pain Treatmentpain Is A Complex Sensory And Emotional Experience Typically Associated With Potential Or Actual Tissue Damage. Understanding Pain Is Crucial For Developing Effective Strategies For Pain Management And Improving The Quality Of Life For Individuals Experiencing Chronic Or Acute Pain. Funded By The European Innovation Council, The Tafalgie Project Is Introducing A Breakthrough In Non-Opioid Analgesics For Pain Treatment. The Innovation Is Based On The Tafa4 Protein, A Strong Modulator In Pain Transmission. The Exogenous Administration Of Tafa4 Or Its Derivatives Diminishes Pain. Tafalgie Hopes To Provide Patients With More Effective, Well-Tolerated, Non-Addictive And Long-Term Solutions For Acute Pain Relief (Mild, Moderate And Severe) And The Prevention Of Chronic Pain.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 17 388 832,00
Eu Contribution
€ 2 499 999,00
Coordinated By
Tafalgie Therapeutics
France
Start Date
1 March 2024
End Date
30 November 2026
Objective
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal. Our ambition: to become the reference player in the field of pain medication by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of first-in-class polypeptides derived from TAFA4 and its peptide derivatives. We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate, and severe -, as well as for the prevention of chronic pain.
